3. Alvin CP. Diabetes Mellitus. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Dan L, Longo L, Jameson L, Loscalzo L, eds. Harrison’s principles of internal medicine. 17th ed. p. 2275–2304. New York: McGraw-Hill companies, 2008.
4. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J ClinEndocrinol Metab 86:4047–4058, 2001.
5. Wang WQ, Ip TP, Lam KS. Changing prevalence of retinopathy in newly diagnosed non-insulin dependent diabetes mellitus patients in Hong Kong. Diabetes Res Clin Pract 39:185–191, 1998.
6. Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-hispanic whites with type 2 diabetes?: a U.S. population study. Diabetes Care 21:1230–1235, 1998.
7. Rajala U, Laakso M, Qiao Q, Keinänen-Kiukaanniemi S. Prevalence of retinopathy in people with diabetes, impaired glucose tolerance, and normal glucose tolerance. Diabetes Care 21:1664–1669, 1998.
8. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, Turner RC. United Kingdom prospective diabetes study, 30: diabetic retinopathy at diagnosis of non-insulindependent diabetes mellitus and associated risk factors. Arch Ophthalmol 116:297–303, 1998.
9. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15:815–819, 1992.
10. Ballard DJ, Humphrey LL, Melton LJ 3rd, Frohnert PP, Chu PC, O’Fallon WM, Palumbo PJ. Epidemiology of persistent proteinuria in type II diabetes mellitus: population-based study in Rochester, Minnesota. Diabetes 37:405–412, 1988.
11. Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care 12:464–474, 1989.
13. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350, 2001.
14. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care 20:537–544, 1997.
15. Pauker SG. Deciding about screening. Ann Intern Med 118:901–902, 1993.
16. Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197, 1997.
17. American diabetes association. Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69, 2010.
18. Van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Polak BC. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Arch Ophthalmol 121:245–251, 2003.
20. DCCT Research Group. The association between glycemic exposure and longterm diabetes complications in the Diabetes Control and Complications Trial. Diabetes 44:968–983, 1995.
22. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program. Diabetes Care 30:2453–2457, 2007.
23. Likhari T, Gama R. Glycaemia-independent ethnic differences in HbA(1c) in subjects with impaired glucose tolerance. Diabet Med 26:1068–1069, 2009.
24. World health Oragnization. Screening for type 2 diabetes: report of a WHO and international diabetes federation meeting. Geneva: World Health Organization, 2003.
25. World health Oragnization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation: part 1. diagnosis and classification of diabetes mellitus Geneva: World health Organization; 1999.
26. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE. The national glycohemoglobin standardization program: a five year progress report. Clin Chem 47:1985–1992, 2001.
27. Davidson MB, Schriger DL. Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. Diabetes Res Clin Pract 87:415–421, 2010.
28. Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of Type 2 diabetes: a systemic review. Diabet Med 24:333–343, 2007.
29. Buell C, Kermah D, Davidson MB. Utility of A1C for diabetes screening in the 1999-2004 NHANES population. Diabetes Care 30:2233–2235, 2007.
30. 배지철, 박철영, 오기원, 박성우, 김지훈, 이원영, 김선우, 최은숙, 이은정, 김원준, 박세은, 유승현. 서울의 한 대학병원에서 당뇨병을 예측하는 당화혈색소 값의 분석. Korean Diabetes J 33:503–510, 2009.
32. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, Yoo SJ, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim HS, Lee IK, Bonner-Weir S. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300–2308, 2003.
33. McCarter RJ, Hempe JM, Chalew SA. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the diabetes control and complications trial. Diabetes Care 29:352–355, 2006.
34. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program. Diabetes Care 30:2453–2457, 2007.